To assess the effect on TGF-β signaling in alveolar macrophages collected via bronchoalveolar lavage (BAL) from healthy participants following 7 days of dosing
Latest Information Update: 27 Aug 2024
At a glance
- Drugs Bexotegrast (Primary)
- Indications Idiopathic pulmonary fibrosis; Primary biliary cirrhosis; Primary sclerosing cholangitis
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 26 Aug 2024 According to a Pliant Therapeutics media release, Safety and tolerability of bexotegrast in Phase 2 trials of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) will be presented at the European Respiratory Society (ERS) International Congress 2024. The Congress will take place in Vienna, Austria from September 7 - 11, 2024.
- 22 Jul 2022 New trial record